UPDATE : Friday, August 23, 2019
상단여백
‘Drug firm’s pick of doctor to attend conference overseas illegal’ by Kim Yun-mi 2019-08-22 15:45
Rivalry among PARP inhibitors intense in ovarian cancer treatment by Kim Yun-mi 2019-08-19 14:00
Diabetes drug Jardiance pressures heart failure treatment Entresto by Kim Yun-mi 2019-08-09 15:44
Lilly’s anticancer combo drug nears getting insurance benefit by Kim Yun-mi 2019-08-07 15:44
Japanese firms fear boycott may hurt prescription drug sales by Kim Yun-mi 2019-08-06 15:44
라인
Roche, MSD, AstraZeneca: top 3 risers on NASDAQ biotech by Kim Yun-mi 2019-08-06 11:29
Amgen’s lipid-lowering Repatha beats Sanofi’s Praluent in Q2 sales by Kim Yun-mi 2019-08-05 15:37
‘MSD Korea playing tricks to maintain monitoring on salespersons’ by Kim Yun-mi 2019-08-02 15:48
Conflict erupts between employees of Takeda, Shire during merger by Kim Yun-mi 2019-08-02 14:23
‘Recurrent chronic lymphocytic leukemia needs various treatment options’ by Kim Yun-mi 2019-08-01 15:31
라인
Novartis fails to expand heart failure drug Entresto’s indication by Kim Yun-mi 2019-07-31 14:26
‘FDA likely to OK 11 blockbuster candidates in August’ by Kim Yun-mi 2019-07-29 16:55
Takeda’s Zejula poised to change local ovarian cancer treatment market by Kim Yun-mi 2019-07-29 12:04
Will Gilead enter the autoimmune diseases market? by Kim Yun-mi 2019-07-22 17:34
Employees file suit against Galderma Korea by Kim Yun-mi 2019-07-19 15:41
라인
2 cancer immunotherapy makers face different situations in reimbursement talks by Kim Yun-mi 2019-07-18 16:01
Korean pulmonary arterial hypertension patients’ survival far lower than Japanese by Kim Yun-mi 2019-07-15 16:48
Humira permitted for nursing, pregnant patients by Kim Yun-mi 2019-07-11 16:41
‘Patients with myeloproliferative neoplasm unaware of cause before diagnosis’ by Kim Yun-mi 2019-07-02 16:42
BMS Korea files administrative suit to appeal Eliquis price cut by Kim Yun-mi 2019-07-01 14:16
여백
여백
여백
Back to Top